Physician profile
Anil Uberoi
NPI 1427151570
$6,629.53
in general payments reported to CMS, 2019-2025
39 companies · $15.30 in 2025
The $15.30 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,152 · 2020: $1,655 · 2021: $591 · 2022: $355 · 2023: $1,674 · 2024: $187 · 2025: $15.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,877.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,876.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,146.63 | 2019-2023 | Farxiga, Breztri |
| Glaxosmithkline, LLC. | $735.50 | 2019-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $581.80 | 2019-2022 | |
| Novo Nordisk INC | $547.91 | 2019-2023 | Rybelsus, Ozempic |
| Allergan, INC. | $330.16 | 2019-2020 | |
| Astellas Pharma US INC | $310.44 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $304.09 | 2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $301.76 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $243.06 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $223.93 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $185.50 | 2019-2022 | |
| Abbvie INC. | $174.45 | 2021-2023 | Vraylar |
| Pfizer INC. | $163.78 | 2019-2023 | |
| Amgen INC. | $154.36 | 2023-2024 | Repatha, Otezla |
| Amarin Pharma, INC. | $149.61 | 2019 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $141.35 | 2019-2023 | Mounjaro, Trulicity |
| Phathom Pharmaceuticals, INC. | $120.27 | 2024 | Voquezna |
| Sumitomo Pharma America, INC. | $106.17 | 2023 | Aptiom |
| Indivior INC. | $105.12 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $83.20 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $56.05 | 2023 | Gvoke Hypopen |
| Eisai INC. | $52.29 | 2020-2021 | |
| Neurocrine Biosciences, INC. | $43.19 | 2023 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $42.54 | 2019 | |
| Mdd US Operations, LLC | $42.46 | 2019-2020 | |
| Orexo US, INC. | $35.90 | 2023 | Zubsolv |
| Gilead Sciences, INC. | $32.66 | 2019-2023 | |
| Abbott Laboratories | $28.54 | 2021-2023 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.85 | 2019 | |
| Dexcom, INC. | $21.74 | 2023 | Dexcom G6 Transmitter |
| Lundbeck LLC | $21.11 | 2023 | Abilify Maintena |
| Vanda Pharmaceuticals INC. | $16.62 | 2020 | |
| Ferring Pharmaceuticals INC. | $16.25 | 2024 | Adstiladrin |
| Nestle Healthcare Nutrition INC. | $15.47 | 2020 | |
| Exact Sciences Corporation | $15.30 | 2025 | Cologuard Collection Kit |
| Sanofi Pasteur INC. | $13.91 | 2019 | |
| Corcept Therapeutics | $13.80 | 2023 | Korlym |
| Sun Pharmaceutical Industries INC. | $13.66 | 2020 | |
| Hikma Pharmaceuticals USA | $11.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anil Uberoi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.